Ennovate Pharma
Ennovate Pharma is a pre-clinical French biotech developing bispecific antibody therapies for refractory autoimmune and inflammatory disease patients, combining single-cell spatial-omics with proprietary AI/ML algorithms for biomarker discovery, co-founded by Enable Medicine and General Inception.
- Company typePrivate
- Founded2023
- HeadquartersSaint-louis-de-montferrand, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
Ennovate Pharma firmographics
Firmographics- Name
- Ennovate Pharma
- Legal name
- Ennovate Pharma
- Website
- https://ennovatetx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ennovate Pharma is a pre-clinical French biotech developing bispecific antibody therapies for refractory autoimmune and inflammatory disease patients, combining single-cell spatial-omics with proprietary AI/ML algorithms for biomarker discovery, co-founded by Enable Medicine and General Inception.
- Ownership category
- akta.pro rank
Ennovate Pharma industry classification
Industry- Product category
- Biologic Therapeutics Development
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Ennovate Pharma is headquartered
LocationHeadquarters
- HQ city
- Saint-louis-de-montferrand
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Ennovate Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Therapeutic Development and Licensing: Pre-revenue early-stage biotech company developing novel bispecific biologics for autoimmune and inflammatory diseases. Revenue model expected to involve licensing of therapeutic candidates to pharmaceutical partners or commercializing pipeline products upon regulatory approval.
Marketing channels2 records
Ennovate Pharma product offering
Product offeringCore offering
Ennovate Pharma develops next-generation bispecific biologic drug candidates targeting the IL1R pillar for refractory and non-responder autoimmune and inflammatory disease patients. The company combines standard-of-care clinical data with single-cell spatial biology data and proprietary AI/ML algorithms to discover novel biomarkers and engineer bispecific antibody therapeutics. Its pipeline includes preclinical candidates ENNO-01 (Hit), ENNO-02 (Lead), and ENNO-0X (DC stage).
Product overview
Ennovate Pharma is developing a pipeline of next-generation bispecific biologics anchored on the IL1R pillar. The company's therapeutic portfolio includes three bispecific antibody candidates (ENNO-01, ENNO-02, and ENNO-0X) engineered to address the needs of refractory and non-responder patients in inflammatory and autoimmune diseases. The pipeline progresses from Hit through Lead and DC (Design Chemistry) stages, with ENNO-01 progressing toward IND and Phase 1 studies.
Differentiator
Problem solved
Functional benefit
Products and services
- ENNO-01 (Bispecific EV01*EV03) Bispecific therapeutic antibody candidate in preclinical (Hit stage) development, anchored on the IL1R pillar, designed for refractory and non-responder patients in inflammatory diseases.
- ENNO-02 (Bispecific EV01*EV02) Bispecific therapeutic antibody candidate in preclinical (Lead stage) development, anchored on the IL1R pillar, targeting inflammatory disease patients who do not respond to current cytokine-based therapies.
- ENNO-0X (Bispecific EV01*EV0X) Bispecific therapeutic antibody candidate in preclinical (DC stage) development targeting inflammatory diseases through next-generation biologics engineering on the IL1R pillar.
Companies that use Ennovate Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Ennovate Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Ennovate Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Enable MedicinecoreEnable Medicine co-founded Ennovate Pharma, contributing expertise in single-cell spatial-omics platforms and advanced data analysis capabilities for therapeutic discovery.
- General InceptioncoreGeneral Inception co-founded Ennovate Pharma, providing strategic support and potentially contributing to the integration of AI/ML capabilities and biologics development expertise.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
Ennovate Pharma competitors and assessment
Company assessmentEmerging players
- Sonoma Biotherapeutics: Sonoma Biotherapeutics develops engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, leveraging single-cell genomics for target identification. Comparable to Ennovate Pharma in autoimmune/inflammatory focus and use of single-cell biology for target discovery, though the modality (cell therapy vs. bispecific antibody) differs.
- Spyre Therapeutics: Spyre Therapeutics develops engineered biologics, including bispecific antibodies, for inflammatory bowel disease and other gastrointestinal inflammatory conditions. Comparable in modality and inflammatory disease focus to Ennovate Pharma's IL1R-anchored pipeline.
- Pieris Pharmaceuticals (now merged into Palvella Therapeutics): Pieris Pharmaceuticals developed bispecific and multispecific antibody-based therapeutics for respiratory and inflammatory diseases using a proprietary lipocalin-based scaffold. Comparable to Ennovate Pharma in bispecific/multispecific biologic approach to inflammatory diseases.
Direct peers
- AnaptysBio: AnaptysBio discovers and develops antibody therapeutics with a focus on inflammation and immunology, including bispecific antibodies. Comparable in antibody modality and inflammatory disease focus to Ennovate Pharma.
- AbCellera Biologics: AbCellera Biologics operates an antibody discovery platform leveraging single-cell screening and AI/ML to identify therapeutic antibodies, with a growing pipeline of internal and partnered candidates in inflammation and infectious disease. Comparable to Ennovate Pharma's AI/ML + single-cell antibody discovery approach.
- Zymeworks: Zymeworks is a clinical-stage biotechnology company developing multifunctional bispecific and trispecific antibodies, including candidates in inflammation and autoimmune indications. Comparable in bispecific antibody platform focus and therapeutic area to Ennovate Pharma.
- Apogee Therapeutics: Apogee Therapeutics develops bispecific antibodies for inflammatory and immunologic diseases, with programs in atopic dermatitis, asthma, and inflammatory bowel disease. Directly comparable to Ennovate Pharma in modality (bispecific antibodies) and therapeutic area (refractory inflammatory disease).
Broad incumbents
- AbbVie: AbbVie operates one of the largest immunology franchises (Humira, Skyrizi, Rinvoq) and pursues next-generation biologics for autoimmune and inflammatory diseases. Comparable as a broad incumbent dominating the same therapeutic landscape Ennovate Pharma targets.
- Eli Lilly and Company: Eli Lilly is a large biopharmaceutical company with a major immunology franchise (e.g., Taltz, Olumiant) and active bispecific antibody programs including in IL-1/IL-23 axis inflammation. Comparable as a broad incumbent in immunology/inflammation with overlapping target biology to Ennovate Pharma.
Others
- Enable Medicine: Enable Medicine is a co-founder of Ennovate Pharma and operates the single-cell spatial-omics platform underlying Ennovate Pharma's target discovery engine. Listed as a peer because it is the closest direct enabler of Ennovate Pharma's core technology, despite not being a competing therapeutic developer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Ennovate Pharma social profiles
Digital presenceEnnovate Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ennovate Pharma leadership team
Management profileNumber of profiles
Ennovate Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ennovate Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ennovate Pharma
What does Ennovate Pharma do?
Ennovate Pharma develops next-generation bispecific biologic drug candidates targeting the IL1R pillar for refractory and non-responder autoimmune and inflammatory disease patients. The company combines standard-of-care clinical data with single-cell spatial biology data and proprietary AI/ML algorithms to discover novel biomarkers and engineer bispecific antibody therapeutics. Its pipeline includes preclinical candidates ENNO-01 (Hit), ENNO-02 (Lead), and ENNO-0X (DC stage).
Is Ennovate Pharma a public or private company?
Ennovate Pharma is a private company. It is classified as unknown and is currently operating.
When was Ennovate Pharma founded?
Ennovate Pharma was founded in 2023. It employs 1 to 10 people.
Where is Ennovate Pharma based?
Ennovate Pharma is headquartered in Saint-louis-de-montferrand, France, in the Europe region.
How does Ennovate Pharma make money?
One revenue line is on record: therapeutic Development and Licensing.
Who are Ennovate Pharma's main competitors?
Emerging players on record are Sonoma Biotherapeutics, Spyre Therapeutics and Pieris Pharmaceuticals (now merged into Palvella Therapeutics). Direct peers are AnaptysBio, AbCellera Biologics, Zymeworks and Apogee Therapeutics. Broad incumbents are AbbVie and Eli Lilly and Company. Enable Medicine is listed as an others.
Does Ennovate Pharma have an API?
No public API is recorded for Ennovate Pharma.
What industry is Ennovate Pharma in?
Ennovate Pharma's product category is Biologic Therapeutics Development. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.